Valneva

Valneva Net Margin

The Net Profit Margin of Valneva (VLA.PA) as of Sep 17, 2026 is -65.95 %. In the previous year, Net Profit Margin was -7.22 % — a change of 813.22% (lower).

Net Margin

-65.95 %

YoY

813.22%

Last updated:

Net Profit Margin of Valneva is 2026 -65.95 % . Net Profit Margin of Valneva was 2025 -7.22 % . It decreases by 813.22% lower compared to the previous year.

For Valneva, the net margin of -66.0% is down versus -21.1% a few years ago.

The Valneva Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
2.89 EUR
Jan 1, 2019
-1.38 EUR
Jan 1, 2020
-58.37 EUR
Jan 1, 2021
-21.09 EUR
Jan 1, 2022
-39.66 EUR
Jan 1, 2023
-65.99 EUR
Jan 1, 2024
-7.22 EUR
Jan 1, 2025
-65.95 EUR
The Valneva Net Margin history
YEARNet MarginYoY
-65.95 %+813.22%
-7.22 %-89.06%
-65.99 %+66.40%
-39.66 %+88.00%
-21.09 %-63.86%
-58.37 %+4,123.57%
-1.38 %-147.86%
2.89 %-126.48%
-10.91 %-79.14%
-52.29 %+98.73%
-26.31 %-63.02%
-71.15 %+8,884.93%
-0.79 %-81.69%
-4.33 %+904.60%
-0.43 %-54.60%
-0.95 %-52.21%
-1.98 %+183.93%
-0.70 %-82.00%
-3.88 %+3,620.86%
-0.10 %
Access this data via the Eulerpool API

Valneva Stock analysis

What does Valneva do? Valneva SE is a biopharmaceutical company specializing in the development, production, and marketing of vaccines for humans and animals. The company was founded in 2013 through the merger of French biotech company Vivalis and Austrian biotech company Intercell. Valneva focuses on developing vaccines for infectious diseases with a significant global burden but limited commercial demand. They work closely with governments and international organizations to improve access to their vaccines in developing countries. Valneva also has a strong presence in the animal vaccine market, producing vaccines for diseases in livestock and pets. They have developed and marketed several vaccines, including Ixiaro for Japanese encephalitis and VLA15, a vaccine candidate for Lyme disease. Overall, Valneva is an international company with an impressive pipeline of vaccine candidates and a commitment to addressing global health needs. Valneva is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valneva stock

Net Profit Margin of Valneva is -65.95 % in 2026.

Net Profit Margin of Valneva changed from -7.22 % to -65.95 %, representing a 813.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Valneva since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Valneva with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

Margins — Valneva

All Key Metrics — Valneva